Eisai Company, Ltd. Release: Phase III Study of Dacogen® (decitabine) for Injection in Acute Myeloid Leukemia (AML) Presented at American Society of Clinical Oncology
CHICAGO--(BUSINESS WIRE)--Results from the DACO-016 trial of Dacogen® (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO). AML is a life-threatening cancer of the blood for which there are limited treatment options.